peptide backbone is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
==== Agent Abrella ==== Rainian Agent Abrella (レイン星人エージェント・アブレラ, Rein Seijin Ējento Aburera) is a bat-themed arms dealer from Planet Rain and an infamous figure in the intergalactic black market who is known for causing wars in seven galaxies, destroying billions of lives in the process. As his homeworld's name suggests, it is perpetually raining, forcing him to wear a special helmet that produces an artificial rainy environment to sustain himself on other worlds. After arriving on Earth, he offers his services, as well as Mechanoids and Kaijuki, to his fellow Alienizers for the right price. Initially staying in the shadows, Abrella gathers information on the Deka Base from clients who have successfully infiltrated it and escaped with their lives while planning to eventually realize his desire for a "world of...currency and crime". After eventually making his presence known to the Dekarangers and losing a Browgoul he intended to raise to them, Abrella starts taking their interference personally and launches a failed smear campaign against them. Following this, Abrella takes advantage of the Dekarangers' fight with the Alienizer Jellyfis to break four Alienizers out of prison and lead them in taking over the Deka Base. From there, he uses Deka Base Robo to go on a rampage, lure the bulk of S.P.D.'s forces to Earth, and uses their planetary forcefield against them. While the Dekarangers eventually retake Deka Base Robo and use the D-Bazooka to delete Abrella, he was succeeded by his pupil, Agent X, as of the crossover film Mahō Sentai Magiranger vs. Dekaranger.
=== Partnerships === In 2017, the company announced partnerships with major pharmaceutical companies to negotiate lowering prescription drug costs. GoodRx has deep relationships with major pharmacy chains, including Walgreens, Walmart, CVS Caremark, and Publix, to allow customers to use GoodRx discounts and Gold benefits. GoodRx began its partnership with CVS Caremark in July 2023 to automatically apply coupons to insured CVS customers purchasing generic prescriptions at certain locations. In April 2024, GoodRx added Publix into its network, allowing GoodRx Gold members to use their cards at Publix Pharmacies. GoodRx partners with Pharmacy Benefit Management like Caremark, Express Scripts, and MedImpact to apply their savings directly to eligible insurance plans and members. GoodRx partners with companies like Affirm, Benefitfocus, and DoorDash to integrate their services that offer members discounts and financial flexibility for prescriptions. GoodRx also partners with organizations like the American Academy of Family Physicians Foundation to support broader access to care. In October 2022, GoodRx launched Provider Mode, which allows healthcare providers to use the app to compare costs of drugs for patients based on different payment methods and drug alternatives. In 2025, GoodRx partnered with Novo Nordisk to offer discounted cash-pay access to semaglutide products like Ozempic and Wegovy through its platform and participating pharmacies.
== Test tubes == A reduction in glutathione levels was observed following exposure to sidestream smoke in vitro. Glutathione is an antioxidant which resides in the lung after development. Exposure to sidestream smoke for as little as twenty minutes can lead to an increase in contaminant particles within human small airway epithelial cells (SAEC). Cells exposed to sidestream smoke experienced oxidative stress, which further allowed for DNA damage as well as cell transformation and an uncontrolled cell proliferation. Such DNA mutations and uncontrolled cell division resulting from exposure to sidestream smoke may result in cancerous tumours.
Eliminative cleavage of (1→4)-α-D-galacturonan to give oligosaccharides with 4-deoxy-α-D-galact-4-enuronosyl groups at their non-reducing ends The structure and the folding kinetics of one member of this family, pectate lyase C (pelC)1 from Erwinia chrysanthemi has been investigated in some detail,. PelC contains a parallel beta-helix folding motif. The majority of the regular secondary structure is composed of parallel beta-sheets (about 30%). The individual strands of the sheets are connected by unordered loops of varying length. The backbone is then formed by a large helix composed of beta-sheets. There are two disulphide bonds in PelC and 12 proline residues. One of these prolines, Pro220, is involved in a cis peptide bond. The folding mechanism of PelC involves two slow phases that have been attributed to proline isomerization. Some of the proteins in this family are allergens. Allergies are hypersensitivity reactions of the immune system to specific substances called allergens (such as pollen, synthetic materials, dust, stings, drugs, or food) that, in most people, result in no symptoms. A nomenclature system has been established for antigens (allergens) that cause IgE-mediated atopic allergies in humans. This nomenclature system is defined by a designation that is composed of the first three letters of the genus; a space; the first letter of the species name; a space and an Arabic number. In the event that two species names have identical designations, they are discriminated from one another by adding one or more letters (as necessary) to each species designation.
Dunkin' Donuts changed its slogan in March 2006 to "America Runs on Dunkin'". They Might Be Giants songs were featured in a series of advertisements of new products to boost summer sales. In 2006, a series of Dunkin' Donuts commercials referred to the fictional language "Fritalian". "Is it French? Or is it Italian?" sings a chorus of customers facing a long menu of non-English terms. "Perhaps Fritalian?" was created by Hill Holliday to "poke fun at pretentious Starbucks-style coffee chains, with patrons attempting to order hard-to-pronounce lattes." The commercial was interpreted as a deliberate mocking of Starbucks. The commercials' punchline is: "Delicious lattes from Dunkin' Donuts. You order them in English." It has been a point of discussion that latte, cappuccino, and espresso are loanwords from Italian which have no equivalence in English. The commercials, however, refer to the Starbucks ordering language itself, poking fun at words such as grande and venti. Further commercials in 2007 more directly mocked Starbucks, with a customer ordering a "large" and being chastised to use the term "dieci". Rachael Ray starred in commercials for Dunkin' Donuts beginning in 2007. In May 2008, Dunkin' Donuts removed an online advertisement featuring Ray wearing a fringed black-and-white scarf, following criticism from commentator Michelle Malkin and others who claimed the garment resembled a keffiyeh and symbolized support for terrorism. Dunkin' Donuts pulled that commercial off the air, leading to criticism of the company pertaining to special interests.
Sources: en.wikipedia.org
Joseph Stalin initially resisted Lenin's proposal but ultimately accepted it, and with Lenin's agreement he changed the name to the Union of Soviet Socialist Republics (USSR), although all republics began as socialist soviet and did not change to the other order until 1936. In addition, in the regional languages of several republics, the word council or conciliar in the respective language was only quite late changed to an adaptation of the Russian soviet and never in others, e.g. Ukrainian SSR. СССР (in the Latin alphabet: SSSR) is the abbreviation of the Russian-language cognate of USSR, as written in Cyrillic letters. The soviets used this abbreviation so frequently that audiences worldwide became familiar with its meaning. After this, the most common Russian initialization is Союз ССР (transliteration: Soyuz SSR) which essentially translates to Union of SSRs in English. In addition, the Russian short form name Советский Союз (transliteration: Sovyetsky Soyuz, which literally means Soviet Union) is also commonly used, but only in its unabbreviated form. Since the start of the Great Patriotic War at the latest, abbreviating the Russian name of the Soviet Union as СС has been taboo, the reason being that СС as a Russian Cyrillic abbreviation is associated with the infamous Schutzstaffel of Nazi Germany, as SS is in English. One apparent exception was the Russian abbreviation of the Communist Party of the Soviet Union, КПСС (transliteration: KPSS). In English-language media, the state was referred to as the Soviet Union or the USSR.
Congenital deformity – The correction of vascular malformations and cleft lip and palate abnormalities. In vascular malformations, the progression of the disease distorts the skin and the underlying structure of the nose. Cleft lip and cleft palate defects usually distort the size, position, and orientation of the nasal-tip cartilages. Reconstruction of vascular malformations can involve laser treatment of the skin, and surgical excision of the deformed tissues. When the underlying cartilage support structure is disturbed, cartilage grafts and suturing of the native nasal cartilages can help improve nasal aesthetics by re-orienting the nasal tip cartilages; and cartilage-graft refinements to the nose tip are performed as required. Obstructed airways – The restoration of normal breathing by correcting nasal obstruction caused by a cosmetic rhinoplasty wherein nasal cartilages were over-aggressively trimmed, and the nose appears pinched, which compromises nasal potency (airflow), especially when the patient attempts deep inspiration. These grafting techniques restore normal breathing by increasing the size of the nose tip with baton grafts (internal cartilage), and spreader grafts to widen the nasal middle vault. Furthermore, to improve breathing a septoplasty can be performed concurrent to the reconstructive surgery; likewise, if there is turbinate hypertrophy, an inferior turbinectomy can be performed.
=== Sub 1-GHz === D7A utilizes the 433, 868 and 916 MHz frequencies, which are globally available and license-free. Sub 1-GHz is ideal for wireless sensor networking applications, since it penetrates concrete and water, but also has the ability to propagate over very long ranges without requiring a large power draw on a battery. The low input current of typical tag configurations allows operating on coin cell or thin-film batteries.
Aspergillus flavus var. oryzae (キコウジキン / 黄麹菌 'ki kōji-kin'). The growth range of this species includes pH values from below 2 to above 8, a temperature optimum of 32–36 °C, a temperature minimum of 7–9 °C and a temperature maximum of 45–47 °C. The colony color is initially yellow-green, later more or less brown. Aspergillus sojae (醤油麹菌 'shōyu-kōji-kin') Aspergillus tamarii A. oryzae has three α-amylase genes, which allows it to break down starch relatively quickly into glucose. In contrast, A. sojae has only one α-amylase gene under a weak promoter and the CAAT box has a gene expression attenuating mutation (CCAAA instead of CCAAT). In general, A. oryzae has higher levels starch-degrading enzymes (glucosidases) expression than A. sojae. A too-rapid release of glucose from starch at the beginning of fermentation inhibits the growth of the microorganisms in the soy sauce maturation phase, making the slower digestion beneficial to taste. For the breakdown of proteins to amino acids, A. oryzae strain RIB40 has 65 endopeptidase genes and 69 exopeptidase genes, and A. sojae strain SMF134 has 83 endopeptidase genes and 67 exopeptidase genes. Protein-degrading enzymes (proteases) are more strongly expressed in A. sojae than in A. oryzae, consistent with adaptation to protein-rich feed. These genetic differences lead to significant differences in the odor profile. A. sojae has higher enzyme activity of endopolygalacturonase (breaks down plant cell walls) and glutaminase (converts glutamine to glutamate) than A. oryzae. It has 10 glutaminase genes. Various mutants of A.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.